Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek December 27, 2004 Foust et al.	The Cash Heads Home For a one-time tax break, companies could repatriate $300 billion next year. But what will they do with it?
The Motley Fool December 27, 2011 Dan Newman	How These Companies Earned a 22,000% Return A dollar invested in lobbying Congress can give a company fantastic returns.
CFO July 1, 2005 Don Durfee	Out of Exile The tax cut on foreign earnings only seems restrictive. But some companies remain wary.
The Motley Fool June 29, 2011 Morgan Housel	Come Home, Dear Cash Rooting for a repatriation holiday. Big businesses have tons of cash, yet most of it is parked overseas. Worse, they have every incentive to keep it there.
BusinessWeek March 17, 2011 Coy & Drucker	Apple, Google May Profit on a Tax Holiday Those companies and others say they'll bring home billions in earnings -- but only if they get a big tax break.
Reason Aug/Sep 2009 Veronique de Rugy	Destroying Jobs in Order to Save Them: Obama's Corporate Tax "Reforms" Make a Bad Situation Worse. Instead of making the corporate tax system worse, why not reform it? Why not avoid old protectionist tricks such as Buy American provisions and instead let U.S. firms compete abroad without the chains of the U.S. tax code?
The Motley Fool January 16, 2007 Chuck Saletta	All the Money in the World By investing in the foreign firms that benefit from America's outrageous tax laws, you can profit, too.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
BusinessWeek April 12, 2004 Howard Gleckman	Is Kerry's Jobs Proposal Jinxed? Rejiggering foreign taxes is politically savvy, but it won't help unemployment much
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool October 27, 2011 Eric Bleeker	Here's Where Pfizer's Finding Its Growth Let's examine where Pfizer's sales and earnings come from and how its sales abroad have changed over time.
The Motley Fool October 20, 2010 Morgan Housel	Larry Kudlow's Brilliant Idea for a Tax Holiday How about a 5 percent tax holiday to bring foreign earnings back home?
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool July 13, 2010 Selena Maranjian	Will Taxes Soon Skyrocket? The situation may not be as dire as it seems.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool January 19, 2005 Chris Mallon	Bring Home the Billions A one-time corporate tax break could mean money in the bank for big multinationals. Investors ought to be cautious about buying companies based on strong 2005 earnings, and hopefully companies will clearly separate the "real" from the "one-time" in their reporting.
IndustryWeek December 1, 2005	Taxation: Rush To Remit? Section 965, a potentially beneficial tax provision of the U.S. Internal Revenue Code, expires soon. Manufacturers need to determine now whether pursuing it makes financial sense.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
HBS Working Knowledge April 7, 2008 Sean Silverthorne	The Debate over Taxing Foreign Profits Harvard Business School professor Mihir Desai describes how the U.S. taxes corporations' foreign profits, and makes a case for exempting foreign profit from taxes if proper safeguards are put in place.
The Motley Fool December 14, 2005 Steven Mallas	Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way.
BusinessWeek December 3, 2007 Nanette Byrnes	The Taxman Barely Cometh A look at which companies pay the least - and how proposed reforms would affect profits from abroad.
The Motley Fool August 25, 2008 Rich Duprey	Lipitor Marketing Raises Blood Pressure Pfizer continues affinity-group marketing of its best-selling cholesterol drug Lipitor.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool June 16, 2005 Stephen D. Simpson	Farewell, Sweet Vicuron Pfizer purchased promising biotech Vicuron Pharmaceuticals for $29.10 as share in cash. Vicuron shareholders get a nice payday -- nearly 84% premium to its close and a 21% premium to its all-time high. The deal makes sense for Pfizer despite the high sticker price.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
BusinessWeek September 2, 2010 Serena Saitto	Tech Companies Go Shopping Abroad To avoid taxes, some companies are using their cash overseas.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
BusinessWeek November 22, 2004 Mehring & Arndt	Nice Tax Break While It Lasted In March, 2002, Congress passed a bill that let companies take an immediate bonus depreciation allowance on capital investments such as computers and cars. But that bonus is now set to end on January 1.
BusinessWeek November 21, 2005 Howard Gleckman	How Tax Reform Adds Up The President's Advisory Panel on Federal Tax Reform has proposed two ways to clean up the code, and the impact on companies could vary widely.
Entrepreneur September 2006 Mike Hogan	Hit the Jackpot? For once, a cell tax is being lifted. But don't count on such future luck.
The Motley Fool January 19, 2010 Brian Orelli	Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious.
The Motley Fool April 4, 2011 Brian Orelli	Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.